PD173074, a Selective FGFR Inhibitor, Reverses ABCB1-mediated Drug Resistance in Cancer Cells

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2013 May 16

PMID 23673445

Citations 26

Authors

Atish Patel

Amit K Tiwari

Eduardo E Chufan

Kamlesh Sodani

Nagaraju Anreddy

Satyakam Singh

Suresh V Ambudkar

Ralph Stephani

Zhe-Sheng Chen

Affiliations

Soon will be listed here.

Abstract

Purpose: Specific tyrosine kinase inhibitors were recently reported to modulate the activity of ABC transporters, leading to an increase in the intracellular concentration of their substrate drugs. In this study, we determine whether PD173074, a specific fibroblast growth factor receptor (FGFR) inhibitor, could reverse ABC transporter-mediated multidrug resistance.

Methods: 3-(4,5-Dimethylthiazol-yl)-2,5-diphenyllapatinibrazolium bromide assay was used to determine the effect of PD173074 on reversal of ABC transporter-mediated multidrug resistance (MDR). In addition, [³H]-paclitaxel accumulation/efflux assay, western blotting analysis, ATPase, and photoaffinity labeling assays were done to study the interaction of PD173074 on ABC transporters.

Results: PD173074 significantly sensitized both ABCB1-transfected and drug-selected cell lines overexpressing this transporter to substrate anticancer drugs colchicine, paclitaxel, and vincristine. This effect of PD173074 is specific to ABCB1, as no significant interaction was detected with other ABC transporters such as ABCC1 and ABCG2. The observed reversal effect seems to be primarily due to the decreased active efflux of [³H]-paclitaxel in ABCB1 overexpressing cells observed in efflux assay. In addition, no significant change in the ABCB1 expression was observed when ABCB1 overexpressing cells were exposed to 5 μM PD173074 for up to 3 days, thereby further suggesting its role in modulating the function of the transporter. In addition, PD173074 stimulated the ATPase activity of ABCB1 in a concentration-dependent manner, indicating a direct interaction with the transporter. Interestingly, PD173074 did not inhibit photolabeling of ABCB1 with [¹²⁵I]-iodoarylazidoprazosin (IAAP), showing that it binds at a site different from that of IAAP in the drug-binding pocket.

Conclusions: Here, we report for the first time, PD173074, an inhibitor of the FGFR, to selectively reverse ABCB1 transporter-mediated MDR by directly blocking the efflux function of the transporter.

Citing Articles

Estrogen Receptor Signaling in Breast Cancer.

Miziak P, Baran M, Blaszczak E, Przybyszewska-Podstawka A, Kalafut J, Smok-Kalwat J Cancers (Basel). 2023; 15(19).

PMID: 37835383 PMC: 10572081. DOI: 10.3390/cancers15194689.

FGF1 protects FGFR1-overexpressing cancer cells against drugs targeting tubulin polymerization by activating AKT two independent mechanisms.

Szymczyk J, Sochacka M, Chudy P, Opalinski L, Otlewski J, Zakrzewska M Front Oncol. 2022; 12:1011762.

PMID: 36276073 PMC: 9582358. DOI: 10.3389/fonc.2022.1011762.

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells.

Boichuk S, Dunaev P, Mustafin I, Mani S, Syuzov K, Valeeva E Biomedicines. 2022; 10(3).

PMID: 35327403 PMC: 8945560. DOI: 10.3390/biomedicines10030601.

The Hepatokine FGF21 Increases the Human Spermatozoa Motility.

Bourdon G, Estienne A, Chevaleyre C, Rame C, Guerif F, Brun J Front Endocrinol (Lausanne). 2022; 13:775650.

PMID: 35282437 PMC: 8908098. DOI: 10.3389/fendo.2022.775650.

AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.

Aytatli A, Barlak N, Sanli F, Caglar H, Gundogdu B, Tatar A Cell Oncol (Dordr). 2021; 45(1):41-56.

PMID: 34837170 DOI: 10.1007/s13402-021-00645-6.

References

Krishna R, Mayer L . Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000; 11(4):265-83. DOI: 10.1016/s0928-0987(00)00114-7. View

van Zuylen L, Sparreboom A, van der Gaast A, van der Burg M, van Beurden V, Bol C . The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res. 2000; 6(4):1365-71. View

Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R . The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol. 1999; 128(2):403-11. PMC: 1571648. DOI: 10.1038/sj.bjp.0702807. View

Robey R, Shukla S, Finley E, Oldham R, Barnett D, Ambudkar S . Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol. 2008; 75(6):1302-12. PMC: 2346578. DOI: 10.1016/j.bcp.2007.12.001. View

Ambudkar S . Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol. 1998; 292:504-14. DOI: 10.1016/s0076-6879(98)92039-0. View

Germann U, Shlyakhter D, Mason V, Zelle R, Duffy J, Galullo V . Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs. 1997; 8(2):125-40. DOI: 10.1097/00001813-199702000-00004. View

Liu K, He J, Su X, Sim H, Xie J, Chen X . Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. Int J Cancer. 2012; 132(1):224-35. PMC: 3459133. DOI: 10.1002/ijc.27649. View

Akiyama S, Seth P, Pirker R, Fitzgerald D, Gottesman M, Pastan I . Potentiation of cytotoxic activity of immunotoxins on cultured human cells. Cancer Res. 1985; 45(3):1005-7. View

Dimitroff C, Klohs W, Sharma A, Pera P, Driscoll D, Veith J . Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 2000; 17(2):121-35. DOI: 10.1023/a:1006367032156. View

10.

Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton C, Pritchard-Jones K . BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma. Br J Cancer. 1999; 80(8):1190-6. PMC: 2362368. DOI: 10.1038/sj.bjc.6990485. View

11.

Knights V, Cook S . De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther. 2009; 125(1):105-17. DOI: 10.1016/j.pharmthera.2009.10.001. View

12.

Gottesman M . Mechanisms of cancer drug resistance. Annu Rev Med. 2002; 53:615-27. DOI: 10.1146/annurev.med.53.082901.103929. View

13.

Hamby J, CONNOLLY C, Schroeder M, Winters R, Showalter H, Panek R . Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem. 1997; 40(15):2296-303. DOI: 10.1021/jm970367n. View

14.

Rowinsky E, Smith L, Wang Y, Chaturvedi P, Villalona M, Campbell E . Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol. 1998; 16(9):2964-76. DOI: 10.1200/JCO.1998.16.9.2964. View

15.

Dean M, Rzhetsky A, Allikmets R . The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001; 11(7):1156-66. DOI: 10.1101/gr.184901. View

16.

Leonard G, Polgar O, Bates S . ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs. 2002; 3(11):1652-9. View

17.

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

18.

Pardo O, Latigo J, Jeffery R, Nye E, Poulsom R, Spencer-Dene B . The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res. 2009; 69(22):8645-51. DOI: 10.1158/0008-5472.CAN-09-1576. View

19.

Sauna Z, Ambudkar S . Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci U S A. 2000; 97(6):2515-20. PMC: 15960. DOI: 10.1073/pnas.97.6.2515. View

20.

Shukla S, Robey R, Bates S, Ambudkar S . Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2008; 37(2):359-65. PMC: 2680522. DOI: 10.1124/dmd.108.024612. View